1. Home
  2. CFFN vs CGEM Comparison

CFFN vs CGEM Comparison

Compare CFFN & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Capitol Federal Financial Inc.

CFFN

Capitol Federal Financial Inc.

N/A

Current Price

$8.45

Market Cap

1.1B

Sector

Finance

ML Signal

N/A

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

N/A

Current Price

$11.44

Market Cap

999.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CFFN
CGEM
Founded
1893
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
999.4M
IPO Year
2010
2020

Fundamental Metrics

Financial Performance
Metric
CFFN
CGEM
Price
$8.45
$11.44
Analyst Decision
Buy
Strong Buy
Analyst Count
3
12
Target Price
$9.50
★ $34.60
AVG Volume (30 Days)
★ 1.1M
720.7K
Earning Date
10-28-2026
11-17-2026
Dividend Yield
★ 4.00%
N/A
EPS Growth
★ 79.31
N/A
EPS
★ 0.51
N/A
Revenue
★ $16,300,000.00
N/A
Revenue This Year
$7.98
N/A
Revenue Next Year
$4.98
$300.03
P/E Ratio
$17.22
★ N/A
Revenue Growth
★ 6.54
N/A
52 Week Low
$6.07
$7.25
52 Week High
$9.26
$23.19

Technical Indicators

Market Signals
Indicator
CFFN
CGEM
Relative Strength Index (RSI) 49.29 33.19
Support Level $8.43 N/A
Resistance Level $8.83 $16.31
Average True Range (ATR) 0.21 1.19
MACD 0.03 -0.22
Stochastic Oscillator 47.21 12.69

Price Performance

Historical Comparison
CFFN
CGEM

About CFFN Capitol Federal Financial Inc.

Capitol Federal Financial Inc is a bank holding company that operates through its wholly-owned subsidiary bank. The bank is a community-oriented financial institution that offers a variety of financial services through tens of locations. It mainly serves metropolitan areas within the state of Kansas. The bank performs traditional banking functions such as deposit-taking activities and investing that money in first-lien residential mortgages. It also participates in commercial real estate loans with other lenders, investing those funds in various securities. The vast majority of the bank's loan portfolio is in originated one- to four-family real estate loans. Its primary source of income is net interest income.

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

Share on Social Networks: